| DrugRepV_4684 | 2-C-Methylcytidine | NA | Hepatitis C virus | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Experimental | 30061280 |
| DrugRepV_4685 | 2-C-Methyladenosine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4686 | 2-C-Methylguanosine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4687 | 2-C-Methyluridine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4688 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Approved | 30061280 |
| DrugRepV_4689 | 5-Fluoro-2-deoxyuridine | NA | Cancer | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Approved | 30061280 |
| DrugRepV_4690 | 5-Fluorouridine | NA | Cancer | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Experimental | 30061280 |
| DrugRepV_4691 | 5-Fluorocytidine | NA | Breast Cancer | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Phase IV | 30061280 |
| DrugRepV_4692 | Sofosbuvir | Antiinfectives For Systemic Use | Hepatitis C virus | Acquired immunodeficiency syndrome | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Approved | 30061280 |
| DrugRepV_4693 | 2-O-Methylcytidine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4694 | 3-Deoxyadenosine | NA | Leukemia | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Investigational | 30061280 |
| DrugRepV_4695 | 3-Deoxycytidine | NA | Cancer | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | Phase I | 30061280 |
| DrugRepV_4696 | 3-O-Methylguanosine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4697 | 3-O-Methyluridine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4698 | 9-(beta-D-Arabinofuranosyl)guanine | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4699 | 2-C-Methylcytidine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4700 | 2-C-Methyluridine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4701 | 2-C-Methyladenosine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4702 | 3-Deoxyadenosine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4703 | 5-Fluorocytidine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4704 | 3-O-Methyluridine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4705 | 2-O-Methylcytidine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4706 | 3-Deoxycytidine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4707 | 3-Deoxy-3-fluoroguanosine ProTide | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |
| DrugRepV_4708 | 2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol | NA | NA | Zika virus | NA | NA | Phenotypic assay | Decrease (50 %) | NA | 30061280 |